Jane Street Group LLC Takes Position in Affimed (NASDAQ:AFMD)

Jane Street Group LLC acquired a new stake in Affimed (NASDAQ:AFMD) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,240 shares of the biopharmaceutical company’s stock, valued at approximately $44,000.

Several other large investors have also made changes to their positions in the business. Point72 Asset Management L.P. boosted its holdings in shares of Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the last quarter. FMR LLC boosted its holdings in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 4,086 shares during the last quarter. Intellectus Partners LLC boosted its holdings in shares of Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 10,250 shares during the last quarter. Finally, Choreo LLC purchased a new stake in Affimed during the second quarter worth $54,000. 30.82% of the stock is owned by hedge funds and other institutional investors.

Affimed Stock Up 0.9 %

NASDAQ:AFMD opened at $1.08 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93. The company has a fifty day moving average of $2.15 and a two-hundred day moving average of $3.41. Affimed has a fifty-two week low of $1.06 and a fifty-two week high of $8.95.

Analysts Set New Price Targets

AFMD has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Affimed in a report on Tuesday, December 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. Stifel Nicolaus lowered their price target on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, November 15th. Finally, Wells Fargo & Company lowered their price target on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.